Invizyne Technologies Inc. Files S-1/A Amendment

TL;DR

Invizyne filed an S-1/A amendment, looks like they're still working on going public.

AI Summary

Invizyne Technologies Inc. filed an S-1/A amendment on October 21, 2024, for its registration statement. The company, incorporated in Nevada, is in the biological products sector and is headquartered in Monrovia, California. This filing is an amendment to a previous registration, indicating ongoing efforts to register securities for public offering.

Why It Matters

This filing is a step in the process for Invizyne Technologies Inc. to potentially offer its securities to the public, which could impact its future funding and stock market presence.

Risk Assessment

Risk Level: medium — As an S-1/A filing, it indicates a company is in the process of going public or has ongoing registration requirements, which inherently carries market and regulatory risks.

Key Numbers

• 333-276987 — SEC File Number (Identifies the specific registration filing with the SEC.)
• 20241021 — Filing Date (The date this amendment was officially filed with the SEC.)

Key Players & Entities

• Invizyne Technologies Inc. (company) — Registrant
• Michael Heltzen (person) — Chief Executive Officer
• Andrew Hudders (person) — Legal Counsel
• Aaron A. Grunfeld (person) — Legal Counsel
• 333-276987 (dollar_amount) — SEC File Number
• 20241021 (dollar_amount) — Filing Date

FAQ

Key Financial Figures

• $0.000001 — 0 shares of its common stock, par value $0.000001 (“Common Stock”). Each shar
• $8.00 — s being offered at a price per share of $8.00. The public offering price was determin
• $0.125 — offered and sold at a purchase price of $0.125 per Warrant. The Private Warrants will
• $23,047 — are expected to be up to approximately $23,047, and if the Private Warrants are fully
• $1,475,000 — for cash the Company will receive up to $1,475,000. The offer and sale of the Private Warr
• $200,000 — its accountable expenses, not to exceed $200,000. We will pay the qualified independent
• $100,000 — lified independent underwriter a fee of $100,000, of which $25,000 has been paid in adva
• $25,000 — underwriter a fee of $100,000, of which $25,000 has been paid in advance. The registrat
• $10.00 — e underwriters, at an exercise price of $10.00 (125% of the public offering price). Se
• $1,380,000 — scounts and commissions payable will be $1,380,000 and the total proceeds net of discounts
• $15,870,000 — ssions, to us, before expenses, will be $15,870,000. The underwriter expects to deliver t

Filing Documents

• forms-1a.htm (S-1/A) — 1962KB
• ex4-5.htm (EX-4.5) — 143KB
• ex5-1.htm (EX-5.1) — 17KB
• ex10-7.htm (EX-10.7) — 211KB
• ex23-2.htm (EX-23.2) — 4KB
• ex107-1.htm (EX-FILING FEES) — 46KB
• forms-1a_002.jpg (GRAPHIC) — 15KB
• forms-1a_001.jpg (GRAPHIC) — 6KB
• 0001493152-24-041726.txt ( ) — 2413KB

Use of Proceeds

Use of Proceeds 25 Dividend Policy 25 Capitalization 25

Dilution

Dilution 26 Management’s Discussion and Analysis of Financial Condition and Results of Operations 27

Business

Business 35 Management 47

Executive Compensation

Executive Compensation 53 Certain Relationships and Related Party Transactions 55 Principal Shareholders 55 Description of Capital 56

Underwriting

Underwriting (Conflicts of Interest) 59 Sales of Restricted Securities and Rule 144 63 Legal Matters 64 Experts 64 Additional Information 64 Index to Consolidated Financial Statements F-1 Neither we nor the underwriter have authorized anyone to provide information different from that contained in this prospectus, any amendment or supplement to this prospectus or in any free writing prospectus prepared by us or on our behalf. Neither we nor the underwriter take any responsibility for, and can provide no assurance as to the reliability of, any information other than the information in this prospectus, any amendment or supplement to this prospectus, and any free writing prospectus prepared by us or on our behalf. Neither the delivery of this prospectus nor the sale of the shares of Common Stock means that information contained in this prospectus is correct after the date of this prospectus. This prospectus is not an offer to sell or the solicitation of an offer to buy the shares of Common Stock in any circumstances under which such offer or solicitation is unlawful. You should rely only on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to which we have referred you. Neither we nor the underwriter have authorized anyone to provide you with information that is different. We and the underwriter are offering to sell the shares of Common Stock, and seeking offers to buy the shares of Common Stock, only in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of the shares of Common Stock. For investors outside of the United States: Neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the

View Full Filing

View this S-1/A filing on SEC EDGAR